{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:29:24Z","timestamp":1793964564800,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bortezomib, lenalidomide, and dexamethasone induction chemotherapy (VRd), followed by autologous stem cell transplantation (ASCT), are the standard of care for patients with newly diagnosed multiple myeloma (NDMM). Pomalidomide is currently approved for relapsed-refractory multiple myeloma. This single-arm, open-label, phase 2 study was the prospective evaluation of the efficacy and safety of bortezomib, pomalidomide, and dexamethasone (VPd) induction for NDMM. We used Fleming\u2019s two-stage design for sample size calculation. We included transplant-eligible and ineligible patients aged 18\u201375 years in the study. The patients received four cycles of VPd induction followed by response assessment. Thirty-four patients were included in the study, of which 31 completed all four cycles of induction. The median age was 52 years (32\u201372). Thirty (91%) patients had multiple myeloma, and three had multiple plasmacytomas with less than 10% bone marrow involvement. Nine (27%) had ISS-I, 9 (27%) had ISS-II, and 15 (46%) had ISS-III myeloma. Three patients had high-risk cytogenetic abnormalities. After four cycles of VPd induction, ten patients (32%) achieved stringent CR, nine had CR (29%), eight (26%) had VGPR, and 4 (13%) had PR. Fifteen (48%) had a complete metabolic response (CMR) on PET-CT. Two patients developed SAEs. Anemia was the most common hematological toxicity. Peripheral neuropathy and constipation were the most common non-hematological toxicities. Patients with \u2265VGPR had significantly better 12-month PFS than those with PR. Patients with \u2265VGPR and CMR on PET-CT had significantly better 12-month OS. Our study showed VPd induction is safe and efficacious in NDMM. Further Phase 3 studies are necessary to establish the superiority and survival benefits.<\/jats:p>","DOI":"10.1038\/s41408-023-00816-8","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T09:03:49Z","timestamp":1679648629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-1789","authenticated-orcid":false,"given":"Fen","family":"Saj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadav","family":"Nisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhee","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanapathi","family":"Halanaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"816_CR1","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, et al. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019;37:1228\u201363.","journal-title":"J Clin Oncol."},{"key":"816_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-018-0065-8","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:1\u20137.","journal-title":"Blood Cancer J"},{"key":"816_CR3","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3324\/haematol.11534","volume":"92","author":"HJK van de Velde","year":"2007","unstructured":"van de Velde HJK, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399\u2013406.","journal-title":"Haematologica"},{"key":"816_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Cancer Netw. 2022;20:8\u201319.","journal-title":"J Natl Compr Cancer Netw"},{"key":"816_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosi\u00f1ol","year":"2019","unstructured":"Rosi\u00f1ol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hern\u00e1ndez MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134:1337\u201345.","journal-title":"Blood"},{"key":"816_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936\u201345.","journal-title":"Blood"},{"key":"816_CR7","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood.2020007522","volume":"136","author":"JK Jasielec","year":"2020","unstructured":"Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020;136:2513\u201323.","journal-title":"Blood"},{"key":"816_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781\u201394.","journal-title":"Lancet Oncol"},{"key":"816_CR9","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2018.77.9637","volume":"36","author":"SA Holstein","year":"2018","unstructured":"Holstein SA, Hillengass J, McCarthy PL. Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase. J Clin Oncol. 2018;36:2101\u20134.","journal-title":"J Clin Oncol"},{"key":"816_CR10","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326\u201335.","journal-title":"Leukemia"},{"key":"816_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjh.13905","volume":"172","author":"E Rychak","year":"2016","unstructured":"Rychak E, Mendy D, Shi T, Ning Y, Leisten J, Lu L, et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol. 2016;172:889\u2013901.","journal-title":"Br J Haematol."},{"key":"816_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2014.238","volume":"29","author":"EM Ocio","year":"2015","unstructured":"Ocio EM, Fern\u00e1ndez-L\u00e1zaro D, San-Segundo L, L\u00f3pez-Corral L, Corchete LA, Guti\u00e9rrez NC, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015;29:705\u201314.","journal-title":"Leukemia"},{"key":"816_CR13","unstructured":"International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma [Internet]. Int. Myeloma Found. 2022. https:\/\/www.myeloma.org\/resource-library\/international-myeloma-working-group-imwg-uniform-response-criteria-multiple."},{"key":"816_CR14","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"JJ Lahuerta","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB, Cord\u00f3n L, Cedena MT, Puig N, et al. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA\/GEM Clinical Trials. J Clin Oncol. 2017;35:2900\u201310.","journal-title":"J Clin Oncol."},{"key":"816_CR15","doi-asserted-by":"publisher","first-page":"LBA3","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA3","volume":"38","author":"S Kumar","year":"2020","unstructured":"Kumar S, Jacobus SJ, Cohen AD, Weiss M, Callander NS, Singh AA, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRD) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. J Clin Oncol. 2020;38:LBA3.","journal-title":"J Clin Oncol."},{"key":"816_CR16","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1182\/blood-2021-151718","volume":"138","author":"VS Radhakrishnan","year":"2021","unstructured":"Radhakrishnan VS, Tamboli N, Das S, Garg JK, Nag A, Bhave SJ, et al. Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Early Safety Data from an Ongoing Single Arm Phase-II Investigator-Initiated Clinical Trial (PRIME Study). Blood. 2021;138:2752.","journal-title":"Blood"},{"key":"816_CR17","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1182\/blood-2019-125134","volume":"134","author":"E Zamagni","year":"2019","unstructured":"Zamagni E, Nanni C, Gay F, Dozza L, Rota Scalabrini D, Omed\u00e9 P, et al. MRD Evaluation By PET\/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial. Blood. 2019;134:4321.","journal-title":"Blood"},{"key":"816_CR18","doi-asserted-by":"publisher","first-page":"e0237155","DOI":"10.1371\/journal.pone.0237155","volume":"15","author":"MT Cedena","year":"2020","unstructured":"Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, et al. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PloS ONE. 2020;15:e0237155.","journal-title":"PloS ONE"},{"key":"816_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood-2020-137412","volume":"136","author":"E Zamagni","year":"2020","unstructured":"Zamagni E, Nanni C, Gay F, Dozza L, Rota Scalabrini D, D\u2019Agostino M, et al. Impact of Imaging FDG-PET\/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial. Blood. 2020;136:27\u20138.","journal-title":"Blood"},{"key":"816_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/cam4.200","volume":"3","author":"E Culakova","year":"2014","unstructured":"Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, et al. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014;3:434\u201344.","journal-title":"Cancer Med"},{"key":"816_CR21","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","volume":"106","author":"S Lonial","year":"2005","unstructured":"Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106:3777\u201384.","journal-title":"Blood"},{"key":"816_CR22","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.3390\/cancers12092540","volume":"12","author":"E Pancheri","year":"2020","unstructured":"Pancheri E, Guglielmi V, Wilczynski GM, Malatesta M, Tonin P, Tomelleri G, et al. Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. Cancers. 2020;12:2540.","journal-title":"Cancers"},{"key":"816_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-019-0183-y","volume":"9","author":"C Plummer","year":"2019","unstructured":"Plummer C, Driessen C, Szabo Z, Mateos MV. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J. 2019;9:1\u201312.","journal-title":"Blood Cancer J"},{"key":"816_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12288-019-01111-y","volume":"35","author":"U Yanamandra","year":"2019","unstructured":"Yanamandra U, Malhotra P. Stem Cell Transplantation in Multiple Myeloma: Very Much Alive and Kicking. Indian J Hematol Blood Transfus. 2019;35:205\u20137.","journal-title":"Indian J Hematol Blood Transfus."},{"key":"816_CR25","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.bbmt.2020.08.018","volume":"26","author":"AJ Cowan","year":"2020","unstructured":"Cowan AJ, Baldomero H, Atsuta Y, Mikhael J, Aljurf M, Seber A, et al. The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study. Biol Blood Marrow Transplant. 2020;26:2372\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"816_CR26","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.bbmt.2018.08.007","volume":"24","author":"U Kulkarni","year":"2018","unstructured":"Kulkarni U, Devasia AJ, Korula A, Fouzia N, Nisham P, Samoon YJ, et al. Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant. Biol Blood Marrow Transplant. 2018;24:e31\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"816_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","volume":"62","author":"M Braunlin","year":"2021","unstructured":"Braunlin M, Belani R, Buchanan J, Wheeling T, Kim C. Trends in the multiple myeloma treatment landscape and survival: a US analysis using 2011\u20132019 oncology clinic electronic health record data. Leuk Lymphoma. 2021;62:377\u201386.","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00816-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00816-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00816-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T09:04:00Z","timestamp":1679648640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00816-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00816-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"2 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was approved by the institutional ethics committee (JIP\/IEC\/2020\/059) and the Clinical Trials Registry of India (CTRI\/2020\/09\/027547).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics appoval"}}],"article-number":"45"}}